|
 |
|
|
|||
|
 |
|
Nov. 8, 2010 Source: Boehringer Ingelheim news release Two swine industry institutions have come together to form a partnership. Boehringer Ingelheim Vetmedica, Inc. (BIVI) has teamed up with Brock Associates to sponsor the Pork Profit Edge newsletter. "The swine industry as a whole has long relied on the market information provided by Pork Profit Edge to help navigate the market's trends and cycles," says Randy Buller, director of swine marketing. "It's a great opportunity to be able to partner with Brock Associates to sponsor this important swine producer publication." With Doug Harper as editor, Brock Associates has served the swine industry by publishing Pork Profit Edge the past 20 years. The newsletter delivers valuable market and production information to producers and others associated with the pork industry. In addition to a new sponsor, Pork Profit Edge has a new, updated look. The newsletter continues to be a four-page printed newsletter and is mailed to swine producers at the beginning of each month. A market update email is distributed near the 15th of each month. As a service to the industry, BIVI is providing Pork Profit Edge free of charge to swine producers. To request to receive Pork Profit Edge, contact breport@brockreport.com or call (800) 558-3431. Brock Associates, located in Milwaukee, WI, is an agricultural commodity advisory firm that has helped farmers, farm owners and agribusinesses make educated grain marketing and purchasing decisions for 30 years. The Brock Report, a 24-page weekly newsletter, is the firm's flagship publication. Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT, and a member of the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development. Tweet |
|
|
|
|
|
|
|
|
|||||||||||||
